Elizabeth Colantuoni, PhD
- Associate Scientist
- Biostatistics (Primary)
615 N. Wolfe Street
Baltimore, Maryland 21205
PhD, Johns Hopkins Bloomberg School of Public Health, 2007
ScM, North Carolina State University, 1999
My collaborative research focuses on studies of critically ill patients whom are treated within the intensive care unit (ICU), through the OACIS group at Johns Hopkins School of Medicine. Specifically, I am interested in how different baseline and ICU treatments are associated with patient outcomes such as mortality and physical function while the patients are in the ICU. In addition, there is growing knowledge that survivors of critical illness carry the burden of this illness for prolonged periods after ICU and hospital discharge. Therefore, I have been working with long-term follow-up studies among these survivors assessing physical function, mental health and quality of life. Several statistical challenges in these studies include: how to model the intensive longitudinal data generated while the patients are in the ICU (daily or twice daily measurements) when often the exposures are time-varying, and the competing risk of mortality both in and out of the ICU which is especially challenging when the outcome of interest is not a survival event but a continuous or binary outcome.
I am the lead statistician on the TREAT study (Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial). More information on this trial can be found here.
I also work on reviewing and developing statistical methods that leverage prognostic baseline variables to improve precision for estimating the average treatment effect within randomized trials. This is joint work with Michael Rosenblum and several others.
In the past, I worked on multi-stage models for Alzheimer's disease prevalence (work with Ron Brookmeyer), we have developed a web-based tool to project the prevalence of Alzheimer's disease globally, for the US or for other user-specified regions. Check is out HERE
View my CV
- critical care medicine, patient safety, longitudinal data analysis, competing risks, truncation by death, randomized trials, adjustment for baseline variables.
Colantuoni E, Rosenblum M. Leveraging Prognostic Baseline Variables to Gain Precision in Randomized Trials. Statistics in Medicine. 2015. 34(18): 2602-2617. doi: 10.1002/sim.6507.
Milstone AM, Koontz DW, Voskertchian A, Popoola V, Harrelson K, Ross T, Aucott SW, Gilmore MM, Carroll KC, Colantuoni E. Treating Parents to Reduce NICU Transmission of Staphylococcus aureus (TREAT PARENTS) trial: protocol of a multisite randomised, double-blind, placebo-controlled trial. BMJ Open 2015;5:e009274 doi:10.1136/bmjopen-2015-009274.
Needham DM, Colantuoni E, Dinglas VD, Hough CL, Wozniak AW, Jackson JC, Morris PE, Mendez-Tellez PA, Ely EW, Hopkins RO. Rosuvastatin for Delirium and Cognitive Impairment in Sepsis-Associated Acute Respiratory Distress Syndrome: An Ancillary Study to a Randomized Controlled Trial. The Lancet Respiratory Medicine. 2016. In Press.
Bienvenu OJ, Colantuoni E, Mendez-Tellez PA, Shanholtz C, Dennison-Himmelfarb CR, Pronovost PJ, Needham DM. Co-occurrence of and remission from general anxiety, depression, and posttraumatic stress disorder symptoms. Crit Care Med. 2015 Mar;43(3):642-53.
Needham DM, Yang T, Dinglas VD, Mendez-Tellez PA, Shanholtz C, Sevransky JE, Brower RG, Pronovost PJ, Colantuoni E. Timing of Low Tidal Volume Ventilation and ICU Mortality in ARDS: A Prospective Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2015 Jan 15;191(2):177-85. doi: 10.1164/rccm.201409-1598OC.